Literature DB >> 34118057

Clinical presentation and outcomes of COVID-19 in older hospitalised patients assessed by the record-based multidimensional prognostic index, a cross-sectional study.

Ane Borgbjerg Verholt1, Merete Gregersen2, Nuria Gonzalez-Bofill3, Troels K Hansen2, Lotte Ebdrup4, Catherine H Foss2, Lone Winther Lietzen2.   

Abstract

PURPOSE: Older people are the most frequently hospital admitted patients with COVID-19. We aimed to describe the clinical presentation of COVID-19 among frail and nonfrail older hospitalised patients and to evaluate the potential association between frailty and clinical course, decision of treatment level with outcomes change in functional capacity and survival.
METHODS: We performed a multi-center, retrospective cross-sectional cohort study examining data on clinical presentation and frailty-related domains for hospitalised people aged 75 + years with a positive severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) test. Frailty was assessed at admission using record-based MPI (rMPI) and Clinical Frailty Scale (CFS). Decision on treatment level about invasive ventilation and cardiopulmonary resuscitation (CPR), change in CFS-score from admission to discharge, changed need of home care, and in-hospital, 30-day and 90-day mortality were registered.
RESULTS: 100 patients (median age 82 years (IQR 78-86), 56% female) with COVID-19 were included. 54 patients were assessed moderately or severely frail (rMPI-score = 2 or 3) and compared to non-frail (rMPI-score = 1). At admission, frail patients presented more frequently with confusion. At discharge, functional decline measured by change in CFS and increased home care was more prevalent among frail than the non-frail. Decisions about no invasive ventilation or CPR were more prevalent among frail older patients with COVID-19 than non-frail. Ninety-day mortality was 70% among frail patients versus 15% in non-frail.
CONCLUSION: Frailty seems to be associated with confusion, more frequent decisions about treatment level, larger functional decline at discharge and a higher mortality rate among older patients with COVID-19.
© 2021. European Geriatric Medicine Society.

Entities:  

Keywords:  Aged; COVID-19; Cross-sectional study; Frailty; Geriatrics

Mesh:

Year:  2021        PMID: 34118057      PMCID: PMC8196927          DOI: 10.1007/s41999-021-00522-3

Source DB:  PubMed          Journal:  Eur Geriatr Med        ISSN: 1878-7649            Impact factor:   1.710


Background

Since the outbreak of COVID-19 caused by the Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2), older people have been the most frequently admitted patients with COVID-19 to hospitals worldwide [1]. High age and frailty are associated with mortality in older COVID-19 inpatients [1-6]. Patients who died from COVID-19 had a higher prevalence of coronary heart disease, hypertension, diabetes, malnutrition, multi-medication and functional disabilities [5]. Illness severity is an important marker of risk within the COVID-19 cohort and may be one of the most important prognostic factors [6]. In-hospital mortality rates are found between 27 and 31% in adults with COVID-19 [1, 4, 7]. Among patients aged 65 or older, the in-hospital mortality rate was 32% [6], and in frail older patients, up to 65% died within 30 days [8]. Frailty is defined as reduced physiological reserve and can be used to evaluate older patients in terms of risk of adverse outcomes [9, 10]. Findings of Hewitt et al. show the importance of frailty assessment, rather than age, in combination with other measures in the context of COVID-19 (1). There is no consensus on how to measure frailty. Until now, the validated tool Clinical Frailty Scale (CFS) has been preferred in studies identifying frailty in older patients with COVID-19. It is widely used across specialties and has short time-consumption [1–3, 5, 6, 8, 11, 12]. The CFS was in its origin developed to predict mortality. There is a building evidence worldwide that age, co-morbidity and frailty measured by CFS impact the course of the disease negatively in older patients who have been infected with COVID-19. In the COPE study, 49% of a cohort of European hospitalized COVID-19 positive adults were defined as frail corresponding to CFS score 5 or more [1]. In the older patients aged 65 years or older, 76–80% were assessed frail at hospital admission [6, 10]. In geriatric wards, the Multidimensional Prognostic Index (MPI) based on Comprehensive Geriatric Assessment (CGA) [13] is a validated and acknowledged tool [14, 15]. Since the MPI tool consists of components and several assessment tools, including illness severity, it makes identification of frailty rather time-consuming. However, due to the thorough assessment, the tool is valuable when making decisions about treatment level [15]. During the pandemic, lack of intensive care resources has been debated, highlighting the importance of front-line staff to address this important topic at admission in dialog with patients and relatives. Frequent clinical manifestations in COVID-19 patients include cough, dyspnea, fever, sore throat, fatigue, myalgia and headache [16]. In addition, some patients may present with diarrhea, vomiting, taste and smell disturbances, and in few cases pleuritic chest pain [6, 16, 17]. Also, there are characteristic changes on chest X-ray, CT scan and in blood test. However, it is well known that older people often have atypical clinical presentation of infectious diseases [18]. So far, the clinical role of frailty among COVID-19-positive older patients is not fully clarified. Therefore, we aimed to describe the clinical presentations of COVID-19 in older inpatients with regard to frailty measured by the record-based MPI (rMPI) tool [19] and to explore possible associations between frailty level and decision of treatment level, change in physical functional abilities and survival. Subsequently, the predictive values of rMPI and CFS were compared.

Methods

Study population and setting

We undertook a multicenter, retrospective cross-sectional cohort study nested in the Central Denmark Region during the time period between March 1 and May 31, 2020 which equals to the first wave of the pandemic in Denmark. The region consists of 1,3 million inhabitants and approximately 8.5% of the population are 75 years or older [20]. In Denmark, the healthcare system is tax-funded and all acute admissions take place in public hospitals [21]. Due to a unique and universal identification number (Civil Registration Number, CRN) assigned to all inhabitants in Denmark at birth or immigration, and a region-wide use of electronic health records (EHR), it was possible to follow individual patients across hospital admissions and summarize data about home care needs collected in the municipalities of the region. We included all patients 75 years and older with a positive SARS-CoV-2 diagnostic test and an admission to one of the seven hospitals treating acute medical conditions in the Central Denmark Region during the study period. We included the positive SARS-CoV-2 diagnostic test results from all test modalities used during the study period verified by oropharyngeal swaps and lower respiratory tract aspirates, knowing that recommendations and test kits changed rapidly during the study period. During the first wave in Denmark, all nursing home residents with positive COVID-19 test were admitted to hospital. The Danish health care system never reached a point of where patients were denied admission due to age or frailty, rather the strategy was to admit everyone to isolate in-hospital rather than in, e.g., nursing homes.

Data source

Relevant CRNs were retrieved from the Central Denmark Region data warehouse that covers all hospitals in the region [22]. We were able to access the EHR and evaluate information about clinical presentation and measurements in the hospital. Also, from the EHR, we retrieved multidisciplinary assessments and information on preadmission cognitive and functional status and care needs generated in the local municipalities and automatically sent to the hospital at admission. Data were stored in an approved REDCap database at Aarhus University [23].

Assessment

We used the record-based MPI (rMPI) that includes eight domains with weighted scores to assess and divide the patient’s frailty level at admission into low as the non-frail patient group, and moderate and severe as the frail group (“Appendix 1”) [19, 24]. Furthermore, we used the CFS both at admission and at discharge to describe any functional decline in relation to the hospitalization (“Appendix 2”). The rMPI includes assessment of activities of daily living (ADL), mobility and instrumental ADL (IADL) by Functional Recovery Score, cognitive status by Short Portable Mental Status Questionnaire (SPMSQ), co-morbidity by Cumulated Illness Rating Scale—Geriatrics (CIRS-G), Mini-Nutritional Assessment – short form (MNA-SF), pressure sore risk by Exton Smith Scale (ESS), co-habitation status, and number of prescribed medications. We examined these frailty-related domains and disease characteristics for all included patients by review of the patients' EHR. When rMPI score was equal to one, patients were assessed to be non-frail and when equal to two or three, assessed to be frail. CFS is a widely used global clinical measure of fitness and frailty that uses pictographs and clinical descriptions to help clinicians stratify older patients on a nine-point scale [25]. CFS scores 1–4 are regarded not frail, whereas scores 5–9 are increasingly frail. CFS was also assessed after thorough review of the EHRs. Baseline covariates were collected from the EHR in the month leading up to admission and included in the rMPI and CFS, Also, CFS was estimated from descriptions in the EHR at discharge. Further, we identified registered symptoms noted in the EHR at admission, relevant vital measurements and blood tests, and information about decisions on treatment level and life support according to invasive ventilation and cardiopulmonary resuscitation (CPR). The EHR reviews were performed by three specialists in geriatric medicine, who have previously worked with the MPI in a clinical setting. Initially, four EHRs were reviewed by all three specialists to ensure inter-rater reliability. Inconsistencies were identified and debated before further individual assessments were performed.

Statistical methods

The study presents both descriptive data and associations. Descriptive baseline characteristics for categorical variables were calculated as percentages. Continuous variables were calculated using mean values with standard deviations for normally distributed data, and medians with interquartile range for non-normally distributed data. Between frail and non-frail patients, continuous variables were compared and analyzed using Student’s t test for normally distributed variables and the Wilcoxon rank-sum test for non-normally distributed variables. Categorical variables were analyzed using the Pearson’s Chi squared test or Fisher’s exact test. Also, a binary linear regression model was used to compare the frail and non-frail patients’ clinical presentations. The models were adjusted for age and gender. The association between mortality of frailty was analyzed using a multivariable regression model adjusted for the clinical presentations at admission that were related to 30-day mortality (p value < 0.08). The regression models were checked by a receiver operating characteristic (ROC) curve. To compare the discriminative abilities of CFS and rMPI measured at admission, the area under the ROC curve was used to assess the predictive value of 90-day mortality. The ROC curve plots the true-positive rate (sensitivity) against the false-positive rate (1 − specificity) at any given cut-off value. An area under the curve (AUC) of 0.5 indicates no discrimination above chance, whereas an AUC of 1.0 indicates perfect discrimination. A p value < 0.05 was considered statistically significant. All statistical analyses were performed in STATA version 16 [26].

Results

The study population included 113 unique individuals with a positive SARS-CoV-2 test and hospital admission in the study period. Thirteen patients were excluded due to lack of relation between positive SARS-CoV-2 test and hospital admission.

At admission

In Table 1, baseline characteristics including clinical presentations are presented by frailty status. By rMPI rating, 54% of the patients were identified as frail. The frail patients were five years older than the non-frail (p = 0.001). Frail patients had similar symptoms and vital parameters at hospital arrival compared to the non-frail patients with exception of confusion, that was presented in 30% of the frail and only 13% of the non-frail patients (p = 0.05). Of all the patients with confusion, 63% were known with cognitive impairment. Mean hemoglobin level was 0.5 mmol/l lower in the frail patients compared to the non-frail. No other blood test values differed between groups.
Table 1

Age, sex, social status, vital parameters, blood measurements, symptoms and examinations regarding to frailty status measured by record-based Multidimensional Prognostic Index (rMPI) in patients with COVID-19 and aged 75 + years

CharacteristicsAll patients N = 100Non-frail patients (rMPI 1) n = 46Frail patients (rMPI 2 + 3) n = 54Relative Risk or coefficient* (95% CI)p value
Median age, y (IQR)82 (78–86)79.5 (77–84)84.5 (79–89)3.57 (1.50; 5.64)0.001
Female sex (%)5630 (65)26 (48)1.49 (0.93; 2.39)0.10
Social status (%)
 Living with spouse4530 (65)15 (28)0.51 (0.32; 0.81)0.005
 Institution18018 (33)NA
 Living alone3716 (35)21 (39)0.97 (0.56; 1.66)0.91
Co-morbidity (%)
 Low1010 (22)0
 Moderate4331 (67)12 (22)
 Severe475 (11)42 (78)7.26 (3.12–16.9) < 0.001
COVID-19 as suspected referral diagnose (%)7334 (77)39 (74)0.95 (0.76; 1.20)0.67
Symptoms (%)
 Fever6519 (54)16 (46)0.64 (0.36; 1,15)0.14
 Cough5728 (61)29 (54)1.01 (0.75; 1.38)0.93
 Dyspnea5021 (46)29 (54)1.24 (0.82; 1.88)0.31
 Chest pain93 (7)6 (11)1.86 (0.47; 7.31)0.37
 Myalgia1812 (26)6 (11)0.60 (0.26; 1.41)0.24
 Abdominal pain3814 (30)24 (44)1.27 (0.72; 2.23)0.4
 Headache96 (13)3 (6)0.53 (0.13; 2.05)0.35
 Weakness6128 (61)33 (61)0.98 (0.70; 1.36)0.89
 Changed sense of smell/taste000NA
 Confusion226 (13)16 (30)2.34 (1.00; 5.51)0.05
 Fall157 (15)8 (15)0.99 (0.59; 1.65)0.96
 Fatigue2815 (33)13 (24)0.82 (0.52; 1.27)0.37
 Other3014 (30)16 (30)0.98 (0.66–1.46)0.93
Vital parameters, mean (SD)
 Respiratory frequency23.2 (6.4)22.0 (5.9)24.2 (6.7)1.28 (− 1.35; 3.90)0.34
 Body temperature38.1 (1.0)37.9 (1.0)38.1 (1.0)0.22 (− 0.19; 0.64)0.29
 Systolic blood pressure135 (23)139 (23)132 (23) − 9.06 (− 18.7; 0.62)0.07
 Diastolic blood pressure73 (18)79 (21)69 (14) − 9.75 (− 17.2; − 2.32)0.01
 Pulse87 (21)86 (22)88 (21)0.81 (− 8.14; 9.76)0.86
 Saturation without oxygen, n = 6994 (4.1)94 (3.4)93 (4.8) − 1.32 (− 3.54; 0.91)0.24
 Saturation with oxygen, n = 4195 (3.4)95 (2.2)95 (3.9) − 0.18 (− 2.78; 2.42)0.89
Blood measurements, mean (SD)
 C-reactive protein [mg/l]79 (77.1)67 (61)90 (88)29 (− 4.07; 61.5)0.09
 Hemoglobin [mmol/l]7.7 (1.3)8.2 (1.2)7.4 (1.2) − 0.69 (− 1.21; − 0.18)0.001
 Creatinine [µmol/l]105 (51)93 (36)114 (60)17.2 (− 4.32; 38.8)0.12
 LDH [U/l] n =89301 (139)293 (102)308 (166)14.8 (− 49.0; 78.6)0.65
 Alkaline phosphatases [U/l]96 (65)87 (50.8)103 (74)14.3 (− 13.8; 42.3)0.32
 Albumin [g/l] n = 8831 (4.4)32 (4.0)31 (4.7) − 0.96 (− 2.94; 1.01)0.34
Examinations (%)
 Chest X-ray8638 (84)48 (89)1.10 (0.94; 1.28)0.22
 Chest CT-scan2816 (36)12 (22)0.58 (0.29; 1.16)0.12
 Infiltrate verified by X-ray or CT-scan7841 (89)37 (69)0.82 (0.66; 1.00)0.05
  Unilateral2113 (28)8 (14)0.67 (0.31; 1.46)0.32
  Bilateral5728 (61)29 (54)0.84 (0.58; 1.21)0.35
 SARS-CoV-2 verified by swab8740 (87)47 (87)0.99 (0.86; 1.16)0.98
 SARS-CoV-2 verified by tracheal suction2813 (28)15 (28)1.15 (0.61; 2.18)0.67
CFS up to admission, median (IQR)5 (3–6)2.5 (2–3)6 (5–7) < 0.001

*Relative risk ratio is used in comparison of dichotomous variables and coefficient is used in continuous and normal distributed variables

Adjustment of age and sex are applied in both analysis models. Not normal distributed variables are analyzed with Wilcoxon Rank-sum Test and presented with p values only

IQR Interquartile range, SD Standard Deviation, NA Not analysed, CFS Clinical Frailty Score

Age, sex, social status, vital parameters, blood measurements, symptoms and examinations regarding to frailty status measured by record-based Multidimensional Prognostic Index (rMPI) in patients with COVID-19 and aged 75 + years *Relative risk ratio is used in comparison of dichotomous variables and coefficient is used in continuous and normal distributed variables Adjustment of age and sex are applied in both analysis models. Not normal distributed variables are analyzed with Wilcoxon Rank-sum Test and presented with p values only IQR Interquartile range, SD Standard Deviation, NA Not analysed, CFS Clinical Frailty Score

Outcomes

Table 2 shows that registered decisions about treatment level differed between the frail and the non-frail patients. Among frail patients, health care professionals had registered a decision about treatment level in 96% compared to 56% among the non-frail patients. Among the frail patients, 87% had a decision of “no critical care” such as invasive ventilation and 91% had a decision of “no attempt to resuscitation”, whereas among the non-frail it was decided in 17% and 22%, respectively. Median length of hospital stay was 8 days with no difference between groups.
Table 2

Outcomes in 75 + -year-old patients with COVID-19 according to frailty status measured by record-based Multidimensional Prognostic Index (rMPI)

CharacteristicsAll patients N = 100Non-frail patients (rMPI 1) n = 46Frail patients (rMPI 2 + 3) n = 54Relative risk or coefficient* (95% CI)p value
Decision of treatment level7725 (56)52 (96)1.82 (1.40; 2.36) < 0.001
 Opting out of invasive ventilation558 (17)47 (87)5.09 (2.70; 9.62) < 0.001
 Opting out of CPR5810 (22)48 (91)4.22 (2.43; 7.33) < 0.001
Intensive care
 Intensive care unit148 (18)6 (11)0.63 (0.23; 1.72)0.37
 Non-invasive ventilation000NA
Invasive ventilation128 (17)4 (7)0.48 (0.15; 1.55)0.22
Length of hospital stay, median days (IQR)8 (3–16)9 (2–17)7 (4–15)0.66
Change* in CFS score, median (IQR)2 (1–4)1.5 (0–3)3 (1–4)0.02
Need of increased home care after discharge (%)
 Domestic help3519 (41)16 (30)0.70 (0.42; 1.21)0.21
 Personal help3115 (33)16 (30)0.90 (0.50; 1.64)0.74
Hospital readmission within 30 days (%)1410 (25)4 (18)0.78 (0.25; 2.45)0.67
Mortality (%)
 In-hospital376 (13)31 (57)4.68 (2.16; 10.1) < 0.001
 30-day383 (7)35 (65)10.3 (3.41; 31.2) < 0.001
 90-day457 (15)38 (70)4.85 (2.41; 9.76) < 0.001

*Relative risk ratio is used in comparison of dichotomous variables and coefficient is used in continuous and normal distributed variables

Adjustment of age and gender are applied in both analysis models. Not normal distributed variables are analyzed with Wilcoxon Rank-sum Test

and presented with p values only

IQR Interquartile range, SD Standard Deviation, NA Not analysed, CFS Clinical Frailty Score, CPR Cardiopulmonary Resuscitation

Outcomes in 75 + -year-old patients with COVID-19 according to frailty status measured by record-based Multidimensional Prognostic Index (rMPI) *Relative risk ratio is used in comparison of dichotomous variables and coefficient is used in continuous and normal distributed variables Adjustment of age and gender are applied in both analysis models. Not normal distributed variables are analyzed with Wilcoxon Rank-sum Test and presented with p values only IQR Interquartile range, SD Standard Deviation, NA Not analysed, CFS Clinical Frailty Score, CPR Cardiopulmonary Resuscitation The difference between the CFS score at admission and at discharge showed that frail patients had a more pronounced decline in functional capacity than non-frail patients. The loss of functional capacity was followed by an increased need for domestic and personal help after discharge. In-hospital mortality was significantly higher in the frail patients (57% vs. 13%), p < 0.001. All-cause 30-day mortality rate was 65% in the frail group versus 7% in the non-frail groups, and 90-day mortality was 70% among the frail patients and 15% in the non-frail group (p < 0.001). At admission, data showed that temperature above 37.5 °C, tachypnea (> 20 breaths per minute) and systolic blood pressure below 140 mmHg were associated with 30-day mortality; and creatinine more than 100 µmol/l was non-significantly associated with 30-day mortality (Fig. 1). The relative risk of 90-day mortality in the frail patients was 4.85 (95% CI: 2.41–9.76), p < 0.001). None of the mortality-related clinical presentations added higher or lower risk of death to the model. Adjustment for confusion did not alter the risk of 90-day mortality (RR = 0.97 (95% CI: 0.67–1.42), p = 0.89). No difference was found in unplanned 30-day readmission rate according to frailty.
Fig. 1

Prediction of 30-day mortality according to clinical presentations at admission

Prediction of 30-day mortality according to clinical presentations at admission

rMPI versus CFS

Figure 2 illustrates equality of the predictive values of rMPI and CFS measured at admission. Both of the frailty tools were capable of predicting 90-day mortality.
Fig. 2

Receiver Operating Characteristic (ROC) curves illustrate the prediction of 90-day mortality using classification thresholds of Clinical Frailty Scale or Multidimensional Prognostic Index. Area under the ROC curves illustrates accuracy of the predictions

Receiver Operating Characteristic (ROC) curves illustrate the prediction of 90-day mortality using classification thresholds of Clinical Frailty Scale or Multidimensional Prognostic Index. Area under the ROC curves illustrates accuracy of the predictions

Discussion

Clinical presentation

The most frequent clinical presentations of COVID-19 in the 75 + -year-old patients were fever, weakness, coughs and dyspnea. Frailty among these patients seems to have a minor impact on the clinical presentation at admission. However, confusion was more prevalent in the frail compared to the non-frail, and short-term mortality was significantly more present in the frail patients. In an American study, 28% of older patients admitted to an emergency department (ED) with COVID-19 had delirium at presentation [27]. Marengoni et al. found that 27.5% of patients admitted with COVID-19 to an acute geriatric ward in Italy had delirium at hospital admittance [28] which corresponds to the incidence in a Danish study of 80 + -year-old patients with COVID-19 [29]. However, Vrillon et al. found an even higher incidence of confusion/delirium by 71% in patients with COVID-19 aged 85 years or more [30]. Also, the Italian group found that patients with delirium compared to patients with no delirium were four times more likely to die during their hospital stay than those without. The seriousness of delirium during admission for COVID-19 has been investigated in a Brazilian study, where delirium was independently associated with in-hospital death, increased length of stay, and admission to intensive care in older adults [31]. Patients with both frailty and confusion often have a history of known cognitive impairment [32] and we found such an association. Similar to our findings, Karlsson et al. found that most patients displayed classical symptoms of COVID-19: fever, cough, respiratory distress, and fatigue [29]. Lui et al. found fever to be less frequent (78%) among older patients aged 60 years or more compared to younger patients [33], which is consistent with our study where only 65% had fever at admission. We found a tendency towards a lower incidence of fever in the frail patients compared to the non-frail. Since falls are an important predictor of negative health outcome among older patients one could have expected these findings in our study. However, 15% of the patients had a fall leading up to admission with COVID-19. Falls in this acute setting are most likely an acute symptom of severe disease rather than an expression of chronic falling among frail individuals. In the Danish study by Karlsson et al., fall was registered in 8% of the 80 + -year-old patients [29]. Vrillon et al. found a higher fall incidence of 25% prior to COVID-19-related hospitalisations of 85 + years [30]. Looking into larger study populations in the future may provide more details about presence and importance of fall in older COVID-19 patients.

The significance of frailty

Our data indicate that front-line staff do pay more attention to decision on treatment level among frail older patients. Ideally, we believe that all patients should be involved in the decision of treatment level and it should be noted in the patient’s health record when admitted with an acute condition. Continuous attention should be paid to this topic both in pandemics and beyond. Not surprisingly, frail older patients with COVID-19 were found to have a more pronounced decline in functional level and a higher need of home care than the non-frail patients at discharge. More detailed knowledge about declining functional level and potential benefits of early in-hospital rehabilitation efforts is needed, as it has important socio-economic perspectives due to increased expenses. Concordant with our findings, a large multi-centre study found that frailty in COVID-19 patients has been associated with increased care needs at discharge in a large cohort study [37]. In a recent prospective study by Pilotto et al. using bedside MPI, they also found that older patients with COVID-19 in MPI level 3 had a significant higher mortality rate than the patients in MPI level 1 [38]. Besides being a strong predictor of mortality in a Brazil cohort during the first COVID-19 wave, frailty assessment was found to provide extra prognostic information by capturing risk factors apart from known risk factors associated with age, co-morbidity and acute disease [39]. As in the study of Karlsson et al. [29] we found no association between confusion and death. In the blood tests measured at admission, we only found one significant difference, where frail patients presented a lower hemoglobin than the non-frail. Few patients presented bleedings so our finding might be due to a more severe load of co-morbidity in the frail group which can lead to chronical anemia [34]. By analyzing the vital parameters at admission, we can only assume that a systolic blood pressure less than 140 mmHg and a diastolic blood pressure less than 75 mmHg were associated with 30-day mortality due to our small sample size. Nevertheless, emerging studies have demonstrated a high prevalence of hypertension among patients with COVID-19 [35]. At present, there is no clear epidemiological evidence supporting that hypertension itself is an independent risk factor for developing severe disease in patients with COVID-19 [36]. Therefore, these results must be examined in larger studies on frail older patients with COVID-19. In our data, rMPI and CFS showed a fair and equal efficiency to predict 90-day mortality. Our rMPI accuracy in predicting 90-day mortality was as good as the bedside MPI in predicting in-hospital mortality in Pilotto's study [38]. Different settings may impact choice of frailty assessment tool as CFS takes a short time to complete, whereas bedside MPI is more time-consuming. Therefore, CFS might be more appropriately used in the ED screening patients for frailty [10], whereas completing a bedside MPI is valuable as a systematic application of CGA. MPI can be recommended to detangle complex physical and mental health needs among elderly and for early discharge planning in the geriatric wards.

Strengths and limitations

To our knowledge, this is the first study to evaluate change in functional status during hospitalization based on detailed data from EHRs and home care data from municipalities. We realize that since data were collected in the beginning of the pandemic with limited test resources, some frail older inpatients were not diagnosed with COVID-19 and therefore not included in the database. Due to an established public data warehouse, all admitted patients with known COVID-19 disease are enrolled in the cohort. During the study period, efforts were made to bring patients with COVID-19 from nursing home (NH) to hospitals to avoid contamination of cohabitants. The same preventive actions were applied among patients receiving home care. The hospitals in Central Denmark Region and in Denmark as a total did not reach a critical number of patients during the study period and it is not likely that any patients were kept out of hospital due to lack of capacity. Our study has some important limitations that needs to be considered when interpreting the data. The record-based reviews were only performed by one reviewer per patient. However, in a recent study by Hansen et al., rMPI was found to have an acceptable inter-rater reliability and high agreement when compared to bedside-rated MPI [19]. In our study, none of the included hospitals have used standardized screening tools for delirium of whether the confusion was an expression of delirium. We based our assessment on EHR descriptions from receiving nurses and physicians notes and often the description was in agreement with clinical presentation of delirium. Also, despite lack of validation of the tool, we used changes in pre- and post-CFS scores and increased home care as a proxy intending to evaluate the potential functional decline during the hospital stay. We did not account for differences in treatment across hospitals and departments, and also did not account for competing risk of death from other acute or chronical diseases with high mortality that might had led to admission in the first place. This might have introduced bias in our results although we have adjusted for gender and age. Due to restriction on test kits in the beginning of the pandemic, only patients with relevant travel activity to pandemic areas and later only patients with classical symptoms like coughing and dyspnea were tested. Also, one can speculate if people living in a nursing home facility may more often have expressed a will about admission avoidance or restrictions to end-of-life care and therefore has not been admitted, but rather have received palliative care at home. This might have led to underdiagnoses of COVID-19 and therefore potentially limited entrance to this study. Despite the confined number of patients included might restrict the conclusions that can be made based on our results, we believe that the focus on multidimensional frailty assessment is an important piece in the puzzle of COVID-19.

Implications

The included patients presented with a wide range of symptoms when admitted to the hospital. We only found minor differences in the clinical presentation of the disease when comparing frail older patients with non-frail, which is important knowledge when working with geriatric patients in the ED. Our results suggest that COVID-19 in frail patients accelerate functional decline during hospitalization. This calls for further evaluation of impact of pre- and post-discharge rehabilitation. A large excess mortality among frail elderly with COVID-19 calls for both disease preventive actions like vaccinations and application of known hygienic precautions, and continuous improvement of treatment and care of frail older patients with COVID-19 both in-hospital and at home. A systematic use of frailty measurements will shed light on COVID-19 interaction with frailty domains and potentially improve patient-centered approaches. Bedsides, MPI and standardized assessment of delirium among patients with COVID-19 infection are wanted to further investigate possible impacts of frailty on COVID-19 infection. Detailed knowledge about frailty status and frailty interactions with, e.g., co-morbidity enable the interdisciplinary team to closely monitor frailty domains like, e.g., functional status to identify specific interventions aimed to reduce negative health outcomes.

Conclusion

In older patients with COVID-19, it seems that frailty was associated with confusion at admission to hospital. Decision of treatment level about invasive ventilation and cardiopulmonary resuscitation was more prevalent among frail older patients than non-frail. Frail patients experienced more often a decline in physical functional abilities and had a higher risk of short-term mortality than non-frail patients.
Table 3

MPI items and applied data collection methods in the bedside- and record-based ratings

MPI-itemBedside rating data sourcesSolution applied in the record-based rating
C0-habitation

Interviewing patients, relatives and/or home care staff

Medical audit

Medical record audit
No. of drugs

Drug chart review

Interviewing patients, relatives and/or home care staff

Medical record audit

Medical record audit

Drug chart review

Clinical pharmacist notes

FRS-ADL

Physical examination

Clinical observation

Interviewing patients, relatives and/or home care staff

Medical record audit

Medical record audit

Rated as self-sufficient if no information was available

FRS-IADL

Interviewing patients, relatives and/or home care staff

Clinical observation

Physical examination

Medical record audit

Medical record audit

Rated as self-sufficient if no information was available

SPMSQStructured interview (10-item questionnaire)

Medical record audit

Rated as:

“Low” (3 points, score = 0) if no cognitive impairment was described

“moderate” (5 points, score = 0.5) if described as delirious

“High” (10 points, score = 1) if diagnosed with dementia

ESS

Physical examination

Clinical observation

Interviewing patients, relatives and/or home care staff

Medical record audit

Medical record audit

Rated as self-sufficient if no information was available

CIRS-GMedical record auditMedical record audit
MINA-SF

Interviewing patients, relatives and/or home care staff

Physical examination

Clinical observation

Medical record audit

Medical record audit

Neuropsychological prblems were rated:

0 points if the patients was diagnosed with dementia, moderate or severe depression, or treated with anti-dementia drugs or antidepressants

1 point if described mild cogniti ve impairment or mild depression

2 points if no cogniti ve or depressive symptoms were described

If no BMI available, BMI was rated:

0 points if described as underweight, malnouri shed, cachectic, suffering from sarcopenia or atrophy of the muscles

1 point if nutritional status was not described

2 points if described as of normal weight or well-nourished

3 points if described as overweight or obese

MPI-item: The Multidimensional Prognostic Index was an aggregate score based on the eight items

Co-habitation co-habitation status, No. of drugs number of drugs used at admission, FRS-ADL Functional Recovery Score Activities of Daily Living, FRS-IADL Functional Recovery Score Instrumentalized Activities of Daily Living, SPMSQ Short Portable Mental Status Questionnaire, ESS Exton Smith Scale, CIRS-G Cumulative Illness Rating Scale-Geriatrics, MNA-SF Mini Nutritional Assessment-Short Form; BMI: Body Mass Index (kg/m2)

  8 in total

Review 1.  Laparoscopic colposuspension for urinary incontinence in women.

Authors:  Nicola Dean; Gaye Ellis; G Peter Herbison; Don Wilson; Atefeh Mashayekhi
Journal:  Cochrane Database Syst Rev       Date:  2017-07-27

2.  "Part of a great team": Perceptions of geriatrics fellows on doing research during a pandemic.

Authors:  Eugênia Jatene Bou Khazaal Berjeaut; Bruna Macêdo de Carvalho; Márlon Juliano Romero Aliberti; Thiago J Avelino-Silva; Flavia Campora; Wilson Jacob-Filho; Flavia Barreto Garcez
Journal:  J Am Geriatr Soc       Date:  2021-08-14       Impact factor: 5.562

3.  Features of 20 133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: prospective observational cohort study.

Authors:  Annemarie B Docherty; Ewen M Harrison; Christopher A Green; Hayley E Hardwick; Riinu Pius; Lisa Norman; Karl A Holden; Jonathan M Read; Frank Dondelinger; Gail Carson; Laura Merson; James Lee; Daniel Plotkin; Louise Sigfrid; Sophie Halpin; Clare Jackson; Carrol Gamble; Peter W Horby; Jonathan S Nguyen-Van-Tam; Antonia Ho; Clark D Russell; Jake Dunning; Peter Jm Openshaw; J Kenneth Baillie; Malcolm G Semple
Journal:  BMJ       Date:  2020-05-22

4.  The multidimensional prognostic index (MPI) for the prognostic stratification of older inpatients with COVID-19: A multicenter prospective observational cohort study.

Authors:  Alberto Pilotto; Margherita Azzini; Alberto Cella; Giovanni Cenderello; Alberto Castagna; Andrea Pilotto; Romina Custureri; Simone Dini; Sara Tita Farinella; Giovanni Ruotolo; Alessandro Padovani; Carlo Custodero; Nicola Veronese
Journal:  Arch Gerontol Geriatr       Date:  2021-04-05       Impact factor: 3.250

5.  Clinical presentation and mortality in hospitalized patients aged 80+ years with COVID-19-A retrospective cohort study.

Authors:  Linda Katharina Karlsson; Lasse Hjort Jakobsen; Louise Hollensberg; Jesper Ryg; Mette Midttun; Henrik Frederiksen; Andreas Glenthøj; Anette Raskov Kodahl; Joanna Secher-Johnsen; Lene Kongsgaard Nielsen; Nuria Gonzalez Bofill; Fredrikke Christie Knudtzen; Cecilia Margareta Lund
Journal:  Arch Gerontol Geriatr       Date:  2020-12-30       Impact factor: 3.250

6.  Utility of white matter disease and atrophy on routinely acquired brain imaging for prediction of long-term delirium risk: population-based cohort study.

Authors:  Sarah T Pendlebury; Ross J Thomson; Sarah J V Welch; Wilhelm Kuker; Peter M Rothwell
Journal:  Age Ageing       Date:  2022-01-06       Impact factor: 10.668

7.  Delirium in Older Patients With COVID-19 Presenting to the Emergency Department.

Authors:  Maura Kennedy; Benjamin K I Helfand; Ray Yun Gou; Sarah L Gartaganis; Margaret Webb; J Michelle Moccia; Stacey N Bruursema; Belinda Dokic; Brigid McCulloch; Hope Ring; Justin D Margolin; Ellen Zhang; Robert Anderson; Rhonda L Babine; Tammy Hshieh; Ambrose H Wong; R Andrew Taylor; Kathleen Davenport; Brittni Teresi; Tamara G Fong; Sharon K Inouye
Journal:  JAMA Netw Open       Date:  2020-11-02
  8 in total
  5 in total

Review 1.  Biomarkers of aging in real life: three questions on aging and the comprehensive geriatric assessment.

Authors:  Marta Zampino; M Cristina Polidori; Manfred Gogol; Laurence Rubenstein; Luigi Ferrucci; Desmond O'Neill; Alberto Pilotto
Journal:  Geroscience       Date:  2022-07-07       Impact factor: 7.581

2.  Validation of Abbreviated Form of the Multidimensional Prognostic Index (MPI): The BRIEF-MPI Project.

Authors:  Alberto Cella; Nicola Veronese; Carlo Custodero; Alberto Castagna; Lisa A Cammalleri; Walter M Capitano; Luisa Solimando; Luca Carruba; Carlo Sabbà; Giovanni Ruotolo; Mario Barbagallo; Alberto Pilotto
Journal:  Clin Interv Aging       Date:  2022-05-12       Impact factor: 3.829

3.  The Value of Clinical Frailty Scale (CFS) as a Prognostic Tool in Predicting Mortality in COVID-19-A Retrospective Cohort Study.

Authors:  Magdalena Jachymek; Aleksandra Cader; Michał Ptak; Wojciech Witkiewicz; Adam Grzegorz Szymański; Katarzyna Kotfis; Jarosław Kaźmierczak; Aleksandra Szylińska
Journal:  Int J Environ Res Public Health       Date:  2022-01-19       Impact factor: 3.390

4.  Clinical Frailty Scale (CFS) indicated frailty is associated with increased in-hospital and 30-day mortality in COVID-19 patients: a systematic review and meta-analysis.

Authors:  Máté Rottler; Klementina Ocskay; Zoltán Sipos; Anikó Görbe; Marcell Virág; Péter Hegyi; Tihamér Molnár; Bálint Erőss; Tamás Leiner; Zsolt Molnár
Journal:  Ann Intensive Care       Date:  2022-02-20       Impact factor: 10.318

5.  Can the Multidimensional Prognostic Index Improve the Identification of Older Hospitalized Patients with COVID-19 Likely to Benefit from Mechanical Ventilation? An Observational, Prospective, Multicenter Study.

Authors:  Alberto Pilotto; Eva Topinkova; Helena Michalkova; Maria Cristina Polidori; Alberto Cella; Alfonso Cruz-Jentoft; Christine A F von Arnim; Margherita Azzini; Heidi Gruner; Alberto Castagna; Giovanni Cenderello; Romina Custureri; Carlo Custodero; Tania Zieschang; Alessandro Padovani; Elisabet Sanchez-Garcia; Nicola Veronese
Journal:  J Am Med Dir Assoc       Date:  2022-07-01       Impact factor: 7.802

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.